MedTrace Logo

Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines

NCT03140774 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2020-07-15

No results posted yet for this study

Summary

The aim of this study is to investigate the persistence of the vaccine induced immune response between 24 - 60 months following primary vaccination.

The study consists of three cohorts:

Cohort 1: volunteers from the Phase 1 study of the various prime/boost regimes with two viral vectored Ebola vaccines: Ad26-ZEBOV and MVA-BN-Filo vaccines

Cohort 2: volunteers who have been vaccinated previously with Ebola vaccine r-VSV-ZEBOV

Cohort 3: volunteers from the Phase 2 study of 3 prime/boost regimes with Ad26.ZEBOV and MVA-BN-Filo vaccines (VAC52150EBL2001: EVOLVE).

Conditions

  • Ebola Virus Disease

Interventions

BIOLOGICAL

Previously exposed to Ebola vaccine

Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Matthew Snape, FRCPH, MD · Oxford Vaccine Group, University of Oxford

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2020-07-10
Completion
2020-07-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140774 on ClinicalTrials.gov